Monday, February 23, 2009

Suspension of marketing of Raptiva (efalizumab) in Canada

From Health Canada:
This Communication is to inform you about the Health Canada recommendation for EMD Serono Canada Inc. to suspend the commercialization of RAPTIVA in Canada.

EMD Serono Canada Inc., in consultation with Health Canada, has urgent new safety information concerning RAPTIVA (efalizumab).

RAPTIVA is an immunomodulating, humanized monoclonal antibody which was authorized in Canada in 2005 for the treatment of moderate to severe chronic plaque psoriasis in adult patients (18 years or older) who are candidates for systemic therapy or phototherapy.
For Health Professionals
For the Public

No comments: